Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2048 - Anti-tNASP antibodies as a diagnostic marker for malignant tumors

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Translational Research

Presenters

Oleg Alekseev

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

O. Alekseev1, K. Admire2, J. Brogdon2, B. Gorman2, C. Davis2, Z. Vaskalis2

Author affiliations

  • 1 Physiology And Pathophysiology, Campbell University, 27546 - Lillington/US
  • 2 School Of Osteopathic Medicine, Campbell University, 27546 - Lillington/US
More

Resources

Abstract 2048

Background

Nuclear Autoantigenic Sperm Protein (NASP), a facilitator of chromatin assembly, is expressed as two splice variants: tNASP, specific for testis and cancer cells, and sNASP, expressed in all somatic cells. Exposure of tNASP to the immune system induces a robust humoral immune response. We suggested that patients with malignancies have a higher level of serum anti-tNASP antibodies than those without malignancies. We hypothesized that detection of anti-tNASP antibodies in serum can be used as a cancer screening test.

Methods

Sera from cancer patients and healthy individuals (negative control) were tested for the presence of antibodies against tNASP using enzyme-linked immunosorbent assay (ELISA) with a recombinant tNASP fragment as bait. A total of 139 serum samples from patients with a known malignancy were tested. These included bladder (11), brain (12), breast (12), endometrial (10), gastrointestinal (10), lung (10), ovarian (10), prostatic (12), skin (10), soft tissue (12), thyroid (10), or urinary (10) malignancy, as well as sera from 10 control patients with no known cancers (negative control).

Results

The majority of samples (56.5%) demonstrated elevated levels of anti-tNASP antibodies compared to negative control: glioblastoma, astrocytoma, colorectal adenocarcinoma, pulmonary adenocarcinoma, large-cell and squamous cell lung carcinoma, ovarian serous carcinoma, ovarian adenocarcinoma, bladder urothelial and squamous cell carcinoma, adenocarcinoma of the urinary bladder, prostate adenocarcinoma, and endometrial adenocarcinoma. Samples from patients with melanoma, renal, thyroid, breast carcinomas, and different types of sarcomas demonstrated similar levels of anti-tNASP antibodies as control samples.

Conclusions

Serum anti-tNASP antibody levels are markedly elevated in the majority of cancer patients tested as compared to healthy controls. These data demonstrate that detection of anti-tNASP antibodies is a viable diagnostic approach and has the potential to be used as an early noninvasive screening method for detection of multiple cancers.

Clinical trial identification

Legal entity responsible for the study

Oleg Alekseev.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.